The Fred Hutchinson Cancer Research Center (FHCRC) is a comprehensive, multi-disciplinary research center which uses basic and applied research to eliminate cancer as a cause of human suffering. Advances at the FHCRC in the areas of cancer prevention, diagnosis, and treatment are coupled with the progress made toward understanding the mechanisms of neoplastic development as well as basic aspects of cellular and molecular biology common to all organisms. The FHCRC employs over 2,300 faculty and staff and is organized into twenty collaborative programs: Biostatistics, Breast Cancer Research, Cancer Biology, Cancer Prevention Research, Cell Cycle and Growth Control, Clinical Transplant Research, Complications of Cancer Treatment, Developmental Biology, Epidemiology, Gastrointestinal Oncology, the developing program in Genetics, Human Immunogenetics, Immunology, Infectious Diseases, Molecular and Cellular Biology, Molecular Medicine, Molecular Pharmacology, Pediatric Oncology, the developing program in Prostate Cancer Research and Transplantation Biology. The high quality of research conducted in the scientific programs of the FHCRC is reflected in the level of funding from peer-reviewed, research grants and contracts. This application proposes continued support for Cancer Center Support Grant activities including senior leaders, program leaders, staff investigators, planning and evaluation, developmental funding, administration, protocol data review and monitoring, phase I/II trials and 20 shared resources.
The aims of the CCSG is to (1) provide support for the research infrastructure of the FHCRC and (2) promote and stimulate interdisciplinary research through enhanced collaborations among the scientific programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-29
Application #
6489012
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1977-01-01
Project End
2002-12-31
Budget Start
2002-03-13
Budget End
2002-12-31
Support Year
29
Fiscal Year
2002
Total Cost
$6,993,721
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Molina, Yamile; Briant, Katherine J; Sanchez, Janeth I et al. (2018) Knowledge and social engagement change in intention to be screened for colorectal cancer. Ethn Health 23:461-479
Winters, Brian R; Vakar-Lopez, Funda; Brown, Lisha et al. (2018) Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 36:342.e7-342.e14
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655

Showing the most recent 10 out of 1267 publications